Stem definition | Drug id | CAS RN |
---|---|---|
1647 | 51-75-2 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
March 15, 1949 | FDA | RECORDATI RARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pruritus | 433.24 | 53.39 | 80 | 1725 | 3679 | 50599640 |
Application site pain | 356.29 | 53.39 | 68 | 1737 | 3730 | 50599589 |
Application site erythema | 320.02 | 53.39 | 64 | 1741 | 4474 | 50598845 |
Application site discolouration | 231.00 | 53.39 | 37 | 1768 | 713 | 50602606 |
Application site irritation | 196.17 | 53.39 | 36 | 1769 | 1579 | 50601740 |
Skin discolouration | 158.82 | 53.39 | 55 | 1750 | 32702 | 50570617 |
Pruritus | 155.77 | 53.39 | 106 | 1699 | 283462 | 50319857 |
Skin irritation | 144.94 | 53.39 | 37 | 1768 | 7690 | 50595629 |
Erythema | 112.86 | 53.39 | 68 | 1737 | 146346 | 50456973 |
Application site vesicles | 112.84 | 53.39 | 22 | 1783 | 1333 | 50601986 |
Therapy non-responder | 104.94 | 53.39 | 46 | 1759 | 50976 | 50552343 |
Application site dryness | 102.27 | 53.39 | 15 | 1790 | 155 | 50603164 |
Skin burning sensation | 81.32 | 53.39 | 25 | 1780 | 10160 | 50593159 |
Application site discharge | 79.56 | 53.39 | 12 | 1793 | 152 | 50603167 |
Application site exfoliation | 72.36 | 53.39 | 12 | 1793 | 287 | 50603032 |
Application site inflammation | 62.71 | 53.39 | 11 | 1794 | 370 | 50602949 |
Skin hyperpigmentation | 59.83 | 53.39 | 17 | 1788 | 5259 | 50598060 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pruritus | 477.16 | 65.54 | 81 | 1840 | 1216 | 29571390 |
Application site erythema | 418.98 | 65.54 | 78 | 1843 | 2021 | 29570585 |
Application site pain | 364.47 | 65.54 | 67 | 1854 | 1612 | 29570994 |
Pruritus | 211.03 | 65.54 | 116 | 1805 | 116733 | 29455873 |
Application site irritation | 187.97 | 65.54 | 33 | 1888 | 601 | 29572005 |
Skin irritation | 182.86 | 65.54 | 45 | 1876 | 4416 | 29568190 |
Application site vesicles | 172.70 | 65.54 | 30 | 1891 | 512 | 29572094 |
Therapy non-responder | 146.73 | 65.54 | 60 | 1861 | 30851 | 29541755 |
Application site discolouration | 124.64 | 65.54 | 20 | 1901 | 204 | 29572402 |
Erythema | 122.02 | 65.54 | 70 | 1851 | 75536 | 29497070 |
Skin burning sensation | 110.67 | 65.54 | 29 | 1892 | 3644 | 29568962 |
Application site discharge | 94.67 | 65.54 | 15 | 1906 | 140 | 29572466 |
Blister | 88.72 | 65.54 | 37 | 1884 | 19869 | 29552737 |
Skin discolouration | 83.63 | 65.54 | 33 | 1888 | 15376 | 29557230 |
Application site burn | 83.01 | 65.54 | 14 | 1907 | 198 | 29572408 |
Cutaneous T-cell lymphoma | 78.78 | 65.54 | 18 | 1903 | 1275 | 29571331 |
Application site exfoliation | 77.27 | 65.54 | 12 | 1909 | 97 | 29572509 |
Application site swelling | 74.66 | 65.54 | 13 | 1908 | 224 | 29572382 |
Application site erosion | 73.14 | 65.54 | 11 | 1910 | 70 | 29572536 |
Disease progression | 70.14 | 65.54 | 51 | 1870 | 81865 | 29490741 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pruritus | 897.17 | 47.30 | 158 | 3548 | 3381 | 64491645 |
Application site erythema | 732.09 | 47.30 | 139 | 3567 | 4550 | 64490476 |
Application site pain | 682.35 | 47.30 | 129 | 3577 | 4119 | 64490907 |
Application site irritation | 389.61 | 47.30 | 69 | 3637 | 1507 | 64493519 |
Pruritus | 337.10 | 47.30 | 213 | 3493 | 312187 | 64182839 |
Application site discolouration | 333.84 | 47.30 | 54 | 3652 | 666 | 64494360 |
Skin irritation | 302.94 | 47.30 | 76 | 3630 | 9118 | 64485908 |
Application site vesicles | 268.40 | 47.30 | 49 | 3657 | 1273 | 64493753 |
Therapy non-responder | 245.70 | 47.30 | 104 | 3602 | 65795 | 64429231 |
Skin discolouration | 216.94 | 47.30 | 80 | 3626 | 35175 | 64459851 |
Erythema | 214.36 | 47.30 | 133 | 3573 | 186937 | 64308089 |
Skin burning sensation | 184.77 | 47.30 | 53 | 3653 | 10530 | 64484496 |
Application site discharge | 171.21 | 47.30 | 27 | 3679 | 279 | 64494747 |
Application site dryness | 161.55 | 47.30 | 24 | 3682 | 160 | 64494866 |
Application site exfoliation | 126.22 | 47.30 | 21 | 3685 | 310 | 64494716 |
Application site swelling | 118.70 | 47.30 | 22 | 3684 | 620 | 64494406 |
Cutaneous T-cell lymphoma | 116.26 | 47.30 | 27 | 3679 | 2325 | 64492701 |
Disease progression | 107.07 | 47.30 | 78 | 3628 | 141602 | 64353424 |
Blister | 101.07 | 47.30 | 61 | 3645 | 80906 | 64414120 |
Application site erosion | 97.98 | 47.30 | 16 | 3690 | 209 | 64494817 |
Skin hyperpigmentation | 97.47 | 47.30 | 29 | 3677 | 6522 | 64488504 |
Application site burn | 95.65 | 47.30 | 19 | 3687 | 777 | 64494249 |
Dry skin | 94.93 | 47.30 | 50 | 3656 | 51111 | 64443915 |
Application site inflammation | 92.85 | 47.30 | 17 | 3689 | 447 | 64494579 |
Application site rash | 89.03 | 47.30 | 21 | 3685 | 1933 | 64493093 |
Dermatitis | 85.88 | 47.30 | 34 | 3672 | 17995 | 64477031 |
Application site reaction | 73.58 | 47.30 | 15 | 3691 | 700 | 64494326 |
Skin exfoliation | 72.43 | 47.30 | 40 | 3666 | 44845 | 64450181 |
Application site scab | 70.92 | 47.30 | 12 | 3694 | 197 | 64494829 |
Second primary malignancy | 61.31 | 47.30 | 24 | 3682 | 12313 | 64482713 |
Application site haemorrhage | 54.74 | 47.30 | 13 | 3693 | 1231 | 64493795 |
Scab | 53.63 | 47.30 | 20 | 3686 | 9002 | 64486024 |
Cutaneous T-cell lymphoma recurrent | 53.25 | 47.30 | 8 | 3698 | 58 | 64494968 |
Lymphomatoid papulosis | 52.83 | 47.30 | 10 | 3696 | 316 | 64494710 |
None
Source | Code | Description |
---|---|---|
ATC | L01AA05 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrogen mustard analogues |
FDA MoA | N0000000236 | Alkylating Activity |
FDA EPC | N0000175558 | Alkylating Drug |
MeSH PA | D000477 | Alkylating Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018906 | Antineoplastic Agents, Alkylating |
MeSH PA | D002619 | Chemical Warfare Agents |
MeSH PA | D007509 | Irritants |
MeSH PA | D009676 | Noxae |
MeSH PA | D011042 | Poisons |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic lymphoid leukemia, disease | indication | 92814006 | |
Chronic myeloid leukemia | indication | 92818009 | DOID:8552 |
Polycythemia vera | indication | 109992005 | |
Hodgkin's disease | indication | 118599009 | |
Non-Hodgkin's lymphoma | indication | 118601006 | |
Mycosis fungoides | indication | 118618005 | |
Malignant tumor of lung | indication | 363358000 | |
Primary cutaneous T-cell lymphoma | indication | 400122007 | |
Pericardial Malignant Effusions | indication | ||
Peritoneal Malignant Effusions | indication | ||
Pleural Malignant Effusions | indication | ||
Amyloidosis | contraindication | 17602002 | DOID:9120 |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Acute infectious disease | contraindication | 63171007 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Secondary malignant neoplasm of bone marrow | contraindication | 94217008 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Granulocytopenic disorder | contraindication | 417672002 | |
Chemotherapy-Induced Hyperuricemia | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 5.7 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | 8501819 | March 7, 2026 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | 7872050 | July 8, 2029 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
None
None
ID | Source |
---|---|
4019808 | VUID |
N0000147897 | NUI |
D04872 | KEGG_DRUG |
55-86-7 | SECONDARY_CAS_RN |
4017994 | VANDF |
4019808 | VANDF |
C0025033 | UMLSCUI |
CHEBI:28925 | CHEBI |
CHEMBL427 | ChEMBL_ID |
DB00888 | DRUGBANK_ID |
CHEMBL1201001 | ChEMBL_ID |
D008466 | MESH_DESCRIPTOR_UI |
4033 | PUBCHEM_CID |
586 | INN_ID |
7218 | IUPHAR_LIGAND_ID |
50D9XSG0VR | UNII |
155036 | RXNORM |
1972 | MMSL |
29634 | MMSL |
5028 | MMSL |
d01339 | MMSL |
002630 | NDDF |
004816 | NDDF |
29156002 | SNOMEDCT_US |
372692002 | SNOMEDCT_US |
387071000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
VALCHLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69639-120 | GEL | 0.01 g | TOPICAL | NDA | 28 sections |